Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 10/22/25 | Ventyx Biosciences (VTYX) | VTX-3232 for Obesity | Subscribers Only | Subscribers Only | Subscribers Only |
| 10/21/25 | Terns Pharmaceuticals (TERN) | TERN-601 for Obesity | Subscribers Only | Subscribers Only | Subscribers Only |
| 10/20/25 | IO (IOBT) | Cylembio for Melanoma | Subscribers Only | Subscribers Only | Subscribers Only |
| 10/20/25 | Sanofi (SNY) | AlphaMedix for Neuroendocrine Tumors (NET) | Subscribers Only | Subscribers Only | Subscribers Only |
| 10/20/25 | Xcovery | Ensacove for Non-Small Cell Lung Cancer (NSCLC) | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 01/31/2025 | Subscribers Only | Subscribers Only | Trial Announcement - Initiation |
| 01/31/2025 | Subscribers Only | Subscribers Only | Trial Announcement - Initiation |
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/26/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |